Skip to content

Released Nov 12, 2026, after the close

10-Q filed Nov 12, 2026, 43 days after period end · 0001193125-26-458680

Q3 2026 · 10-Q
Revenue$9.10M−6.1% vs Q3 2025−7.5% vs Q2 2026
Net Income-$31.49MN/M vs Q3 2025N/M vs Q2 2026
EPS Diluted-$1.90N/M vs Q3 2025N/M vs Q2 2026
Operating Income-$21,956,000N/M
Operating Cash Flowderived-$22,451,000N/M
Margins · derived
Operating margin-241.3%+258.6 pt vs Q3 2025
Net margin-346.1%+240.5 pt vs Q3 2025

What the release said

Revenue was $9.1 million for the quarter ended September 30, 2026, compared with $9.7 million a year earlier, and total R&D and G&A expenses were $31.0 million, compared with $48.6 million.12

Cash, cash equivalents and marketable securities were $142.2 million as of September 30, 2026, compared with $164.3 million as of June 30, 2026, with runway expected into the first half of 2028.3

A second Astellas dual-payload program began dosing patients, resulting in a $10 million milestone payment received by Sutro in October 2026.4

STRO-006 dosed its first patient in a Phase 1 study in October 2026, with an initial Phase 1 data update anticipated in the second half of 2027.5

Cash, cash equivalents and marketable securities
$142.2 million As of September 30, 2026, compared to $164.3 million as of June 30, 20263
Revenue
$9.1 million Quarter ended September 30, 2026, compared to $9.7 million for quarter ended September 30, 20251
Total R&D and G&A expenses
$31.0 million Quarter ended September 30, 2026, compared to $48.6 million for quarter ended September 30, 20252
Astellas milestone payment
$10 million Received by Sutro in October 2026 after second Astellas program began dosing patients4
Thaler Agent · checked against the filing
Open the reading ›
The release

Same quarter

MetricQ3 2026Q3 2025Q3 2024Q3 2023
Revenue$9.10M$9.69M$8.52M$16.92M
Net Income-$31.49M-$56.86M-$48.79M-$49.28M
EPS Diluted-$1.90-$6.66-$0.59-$0.81

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR